Vol. 7, Issue 7 (2018)
Impact of depression, cognitive impairment and sleep on quality of life in patients with Parkinson’s disease
Sri Ravalika VT, Mohammed Mujtaba, Mohit Tated, Sreekanth Vemula and Rani Samyuktha Velamakanni
Background: Parkinson’s disease is a long term neurodegenerative disorder affecting the central nervous system. It is characterised by tremors, rigidity, akinesia/bradykinesia and paralysis as the condition progresses to its final stages. Objective: The aim of the study is to identify the impact of depression, cognitive impairment and sleep on quality of life in patients with Parkinson disease including the management. Methods: About 100 Parkinson’s patients above 18 years were included in the study. The required data was collected from the patients through direct interview using standard questionnaires such as Unified Parkinson’s Disease Rating Scale (UPDRS), Modified Hoehn and Yahr staging scale, Schwab and England Activities of Daily Living Scale, Non Motor Symptoms Questionnaire, Patient Disease Questionnaire-39 (PDQ-39), the Patient Health Questionnaire-9 (PHQ-9), Mini Mental Scale Examination (MMSE), Parkinson’s disease Sleep Scale (PDSS). Statistical methods like Paired T-test and Pearson’s correlation were used for the interpretation of the data. Results: Out of the all population most of the patients were moderately severe depressed while significant and mild cognitive impairment was reported. Hyper somnolence, hallucinations, distressing dreams and nocturia were most reported disturbances during sleep and overall quality of sleep component reported a decline of 2.1% after follow-up. Most reported non motor symptoms were sleep disturbances, pain, depression and hallucinations. PDQ-39 was used to find the impaired quality of life in parkinson’s patients. Out of 8 components, mobility and emotional wellbeing were major components affected while cognition reported an incline of 3% after follow-up. Association of PDQ-39 and UPDRS, staging, disability, PHQ-9, MMSE, PDSS, NMSQ reveal a great correlation existing which indicates that both motor and non-motor symptoms affect the patients quality of life predominantly. Treatment pattern include a combination of carbidopa and levodopa which was prescribed to 93.7% patients while 13.7% patients reported dyskinesia, 54.7% reported dystonia while 51.6% reported insomnia. Non motor symptoms treatment includes mirtazepne, sequorel and lonazepam. Non pharmacological techniques involved were physiotherapy, lower elastic stockings and soft cervical collar. Conclusion: In conclusion the study evidences the undeniable impact of the non-motor symptoms of Parkinson’s disease on the quality of life of a patient. Hence, through this study we have tried to exhibit the importance of treating non-motor symptoms which may be even more important than the treatment of motor symptoms since it has a direct impact on the psychology of a patient suffering from Parkinson’s disease.
How to cite this article:
Sri Ravalika VT, Mohammed Mujtaba, Mohit Tated, Sreekanth Vemula and Rani Samyuktha Velamakanni. Impact of depression, cognitive impairment and sleep on quality of life in patients with Parkinson’s disease. The Pharma Innovation Journal. 2018; 7(7): 44-56.